Pace® Life Sciences Expands Network by Acquiring New Jersey Laboratory from Curia

Pace® Life Sciences, LLC has officially acquired the Lebanon, New Jersey laboratory facility from Curia, marking a significant expansion for the Pace® Laboratory Network. This move is set to bolster Pace® Life Sciences' foothold in the contract development and manufacturing (CDMO) sector, leveraging over a decade of the site's expertise in biopharma industry partnerships.

Eric Roman, CEO of Pace®, expressed enthusiasm about the acquisition, highlighting the anticipated collaboration benefits with pharma and biopharma clients. Conversely, Curia's CEO, Philip Macnabb, noted the decision to transfer ownership aligns with Curia's focus on its core capabilities in life-changing medicine discovery, development, and manufacturing, while benefiting from Pace®'s analytical service leadership.

The newly acquired site adds to Pace® Life Sciences' network, now comprising 9 locations offering comprehensive analytical services. The addition of the New Jersey laboratory is expected to enhance the company's capacity for crucial FDA-registered services, including analytical chemistry and microbiology.

With the backing of Leonard Green & Partners and Aurora Capital Partners, Pace® Life Sciences' expansion marks a strategic enhancement of its service offerings, positioning it for further collaboration in the development and commercialization of pharmaceutical products.